Compositions and methods
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
1. A method of treating or inhibiting a dysbiosis, comprising administering an effective amount of a composition consisting of a population of germinatable bacterial spores and a pharmaceutically acceptable excipient to a subject, wherein the effective amount of the composition administered to the subject populates the gastrointestinal tract in the subject and augments growth of at least one type of bacteria not detectably present in the composition or in the gastrointestinal tract prior to administration, thereby treating the dysbiosis, inhibiting the dysbiosis, or reducing a severity of at least one symptom of the dysbiosis in the subject.
2. A method of treating or inhibiting a dysbiosis in a subject, comprising administering a composition consisting of a population of germinatable bacterial spores and a pharmaceutically acceptable excipient, wherein the population of germinatable bacterial spores is produced by a) providing a fecal material and b) subjecting the fecal material to a treatment resulting in purification of germinatable bacterial spores in an amount effective to treat the dysbiosis, inhibit the dysbiosis, or reduce a severity of at least one symptom of the dysbiosis in the subject.
3. A method of treating or preventing a dysbiosis in a subject, comprising:
obtaining a fecal material;
treating the fecal material to obtain a purified population of spore-forming bacteria;
generating from the purified population a composition of spore-forming bacteria consisting of a population of germinatable bacterial spores; and
administering the composition to a subject in an amount effective to treat the dysbiosis, prevent the dysbiosis, or reduce the severity of at least one symptom of the dysbiosis in the subject.
4. The method of claim 3 , wherein at least one type of spore-forming bacteria in the composition is not detectably present in the gastrointestinal tract of the subject prior to administration of the composition to the subject.
5. The method of claim 3 , wherein administering the composition results in augmenting growth of at least one type of bacteria not detectably present in the composition or in the gastrointestinal tract prior to administration.
6. The method of claim 3 , wherein administering the composition results in at least two of: i) reduction or elimination of at least one pathogen and/or pathobiont present in the gastrointestinal tract of the subject; ii) engraftment in the gastrointestinal tract of the subject of at least one type of spore-forming bacteria present in the composition; and iii) augmentation of at least one type of spore-forming or non-spore forming bacteria in the gastrointestinal tract of the subject that is not present in the composition.
7. The method of claim 3 , wherein administering the composition results in a reduction or an elimination of at least one pathogen and/or pathobiont present in the gastrointestinal tract and at least one of: i) engraftment in the gastrointestinal tract of the subject of at least one type of spore-forming bacteria present in the therapeutic composition; and ii) augmentation in the gastrointestinal tract of the subject of at least one type of bacteria not present in the therapeutic composition.
8. The method of claim 1 , wherein administration of the composition modulates the microbiota diversity present in the gastrointestinal tract of the subject.
9. The method of claim 1 , wherein the subject has a dysbiosis and the dysbiosis is a gastrointestinal disease, disorder or condition selected from the group consisting of Clostridium difficile -induced diarrhea, irritable bowel syndrome (IBS), colonization with a pathogen or pathobiont, infection with a drug-resistant pathogen or pathobiont, colitis, and Crohn's Disease.
10. The method of claim 1 , wherein the population of germinatable bacterial spores is substantially free of a first pathogenic material or the first pathogenic material is inactive.
11. The method of claim 10 , wherein the population of germinatable bacterial spores is substantially free of a detectable level of a first pathogenic material.
12. The method of claim 1 , wherein the population of germinatable bacterial spores is derived from a fecal material and is substantially free of a residual habitat product of the fecal material.
13. The method of claim 12 , wherein the fecal material is obtained from a healthy subject not having a detectable level of a pathogen or a pathobiont prior to production of the fecal material.
14. The method of claim 1 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 381, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 652, SEQ ID NO. 659, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 839, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 874, SEQ ID NO. 880, SEQ ID NO. 886, SEQ ID NO. 1049, SEQ ID NO. 1591, SEQ ID NO. 1655, SEQ ID NO. 1657, SEQ ID NO. 1670, and SEQ ID NO. 1896.
15. The method of claim 1 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 374, SEQ ID NO. 381, SEQ ID NO. 543, SEQ ID NO. 556, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 646, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 843, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 880, SEQ ID NO. 1045, SEQ ID NO. 1049, SEQ ID NO. 1056, SEQ ID NO. 1415, and SEQ ID NO. 1896.
16. The method of claim 8 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 381, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 652, SEQ ID NO. 659, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 839, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 874, SEQ ID NO. 880, SEQ ID NO. 886, SEQ ID NO. 1049, SEQ ID NO. 1591, SEQ ID NO. 1655, SEQ ID NO. 1657, SEQ ID NO. 1670, and SEQ ID NO. 1896.
17. The method of claim 9 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 381, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 652, SEQ ID NO. 659, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 839, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 874, SEQ ID NO. 880, SEQ ID NO. 886, SEQ ID NO. 1049, SEQ ID NO. 1591, SEQ ID NO. 1655, SEQ ID NO. 1657, SEQ ID NO. 1670, and SEQ ID NO. 1896.
18. The method of claim 8 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 374, SEQ ID NO. 381, SEQ ID NO. 543, SEQ ID NO. 556, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 646, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 843, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 880, SEQ ID NO. 1045, SEQ ID NO. 1049, SEQ ID NO. 1056, SEQ ID NO. 1415, and SEQ ID NO. 1896.
19. The method of claim 9 , wherein the composition consists of at least 1×10 4 colony forming units of germinatable bacterial spores per dose of the composition, and wherein the germinatable bacterial spores consists of at least two bacterial entities comprising 16S rDNA sequences at least 97% identical to the nucleic acid sequences selected from the group consisting of SEQ ID NO. 374, SEQ ID NO. 381, SEQ ID NO. 543, SEQ ID NO. 556, SEQ ID NO. 572, SEQ ID NO. 601, SEQ ID NO. 646, SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 843, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, SEQ ID NO. 880, SEQ ID NO. 1045, SEQ ID NO. 1049, SEQ ID NO. 1056, SEQ ID NO. 1415, and SEQ ID NO. 1896.
20. The method of claim 2 , wherein the dysbiosis is a gastrointestinal disease, disorder or condition selected from the group consisting of Clostridium difficile -induced diarrhea, irritable bowel syndrome (IBS), colonization with a pathogen or pathobiont, infection with a drug-resistant pathogen or pathobiont, colitis, and Crohn's Disease.
21. The method of claim 11 , wherein the detectable level is detected by qPCR.
22. The method of claim 13 , wherein the detectable level is detected by qPCR.
23. The method of claim 12 , wherein the residual habitat product is a virus, fungus, or mycoplasma.
24. The method of claim 1 , wherein the type of bacteria is a species.
25. The method of claim 4 , wherein the type of bacteria is a species.
26. The method of claim 5 , wherein the type of bacteria is a species.
27. The method of claim 6 , wherein the type of bacteria is a species.
28. The method of claim 7 , wherein the type of bacteria is a species.